Cells were treated with lapatinib (0.1, l μmol/L; A), bortezomib (1, 10 nmol/L; B) or lapatinib (0.1, l μmol/L) combined with bortezomib (1, 10 nmol/L) for 72 h. Western blot analysis was done for phosphorylated HER2 (p‐HER2) and total HER2, AKT and p‐AKT, ERK and p‐ERK, p‐4E‐BP1 and total P27. The GAPDH served as a loading control.